3 news items
Cogent Biosciences Reports First Quarter 2024 Financial Results
COGT
7 May 24
D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
COGT
26 Feb 24
impressive effects in key biomarkers of disease burdenAchieved 56% Overall Response Rate (ORR) in TKI-naïve patients, including 86% ORR by Pure
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible
- Prev
- 1
- Next